Pharmaceutical Resources Rival Wins Key Drug Approval

IDEC gets FDA approval for cancer treatment; Computer Associates hit by accounting concerns; plus more of today's stocks to watch

Avant Immunotherapy (AVAN ) says its TP10, a lead complement inhibitor, failed to meet its objectives in a Phase II study in adult patients undergoing high risk cardiac surgery.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.